Damora Therapeutics (NASDAQ: DMRA) net income
Damora Therapeutics reported a net loss of $209.8m for fiscal 2025; in fiscal 2024 it reported a net loss of $21.4m.
Damora Therapeutics's best year of the last 7 was fiscal 2024. It reported a loss in 7 of those 7 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$209.8m | — | — | — |
| 2024 | −$21.4m | — | — | −$18.53 |
| 2023 | −$38.3m | — | — | −$1.44 |
| 2022 | −$61.6m | — | — | −$2.43 |
| 2021 | −$51.8m | — | — | −$2.05 |
| 2020 | −$34.8m | — | — | — |
| 2019 | −$36.5m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Damora Therapeutics net income compared with its sector
By net income for its latest fiscal year, Damora Therapeutics ranks 417th of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 415th | Natera | −$208.2m | −9.0% |
| 416th | Verastem | −$209.5m | −677.6% |
| 417th | Damora Therapeutics | −$209.8m | — |
| 418th | Disc Medicine | −$212.2m | — |
| 419th | Immunome | −$212.4m | −3,060.0% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Damora Therapeutics
- How much did Damora Therapeutics earn in fiscal 2025?
- Damora Therapeutics reported a net loss of $209.8m for fiscal 2025. In fiscal 2024 it reported a net loss of $21.4m.
- Where does Damora Therapeutics rank in its sector by net income?
- It ranks 417th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Damora Therapeutics come from?
- From the annual report (Form 10-K) that Damora Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Damora Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. More on Damora Therapeutics: the Damora Therapeutics page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.